
These products, which are slated for near- to mid-term launches beginning in 2024, have a total addressable market size of…
Work on the new plant is set to begin this year, with full operations provisonally planned for late 2026.
According to the pharma major, it is predicted that one in two of these women and one in four men…
The announcement comes after Sandoz successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2021.
The expansion will support a double-digit increase in our future output capacity for penicillins, the company claims.
The pharma major also informed that the standalone Sandoz would be headquartered in Switzerland and listed on the SIX Swiss…
According to the generic pharmaceutical company, the submitted biosimilar was developed to have the same intravenous (iv) dosage form, route…
The company claims that Sandoz has more than 65 million days of patient experience with Hyrimoz 50 mg/mL worldwide and…
The US FDA Enforcement Report for the week of February 17 said that the class III voluntary recall is nationwide…
The EMA’s acceptance follows recent US FDA regulatory submission acceptance
Proposed biosimilar pegfilgrastim filing is the second of ten regulatory filings planned over the next three years Sandoz, a Novartis…
Sandoz One Source, a patient services centre, was also launched Zarxio by Sandoz, a Novartis company, is now available in…
Sandoz India’s Turbhe plant to down shutters by December 2016
Kurt Nielson (Catalent), Vivek Sharma (Piramal) and Alan Sheppard (IMS Health) join panel
It involves acquisition of GSK’s portfolio of oncology products by Novartis for $16 billion